Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,334 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MRI scan Clear all
Recruiting Phase 2 Interventional

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

NCT07087860
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
Interventions
Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
Other · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 2, 2026, 1:28 AM EDT
Withdrawn Early Phase 1 Interventional

Ga-68 MAA Distribution in PAE Patients

NCT04243824
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Gallium 68 Macro-aggregated albumin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Sep 2, 2026, 1:28 AM EDT
Terminated No phase listed Observational

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

NCT03479125
View directory record Official record
Conditions
Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis, Decompensated Non-Alcoholic Steatohepatitis Cirrhosis, Orthotopic Liver Transplantation
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Rialto, California • Tulsa, Oklahoma • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 2, 2026, 1:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation

NCT02791568
View directory record Official record
Conditions
Pregnancy, Obesity, Preeclampsia
Interventions
Ultrasound Scan, MRI Scan, Ferumoxytol
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 2, 2026, 1:28 AM EDT
Completed Phase 2 Interventional

68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

NCT05176223
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 2, 2026, 1:28 AM EDT
Not listed Phase 1 Interventional

Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis

NCT03278925
View directory record Official record
Conditions
Cirrhosis
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Questionnaire Administration, Ultrasound
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 2, 2026, 1:28 AM EDT
Completed Not applicable Interventional Results available

A Post-Market Study Evaluating the Prodigy MRI and Proclaim Elite MR Conditional SCS Systems

NCT02738840
View directory record Official record
Conditions
Chronic Pain
Interventions
MRI scan
Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Napa, California • Rochester, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 2, 2026, 1:28 AM EDT
Completed Not applicable Interventional Results available

PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer

NCT01892540
View directory record Official record
Conditions
Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
positron emission tomography/computed tomography, PET/MRI, Position Device
Diagnostic Test · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 2, 2026, 1:28 AM EDT
Completed Not applicable Interventional

MRI/MRSI in Risk Assessment of Prostate Cancer Patients

NCT00582543
View directory record Official record
Conditions
Prostate Cancer
Interventions
eMRI/MRSI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2011 · Synced Sep 2, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Results available

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

NCT03113617
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Andrei Iagaru
Other
Eligibility
19 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 2, 2026, 1:28 AM EDT
Recruiting Phase 3 Interventional

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 25 Years
Enrollment
5,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
203
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 1:28 AM EDT
Recruiting Phase 2 Interventional

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

NCT07423585
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Magnetic Resonance Imaging, Multigated Acquisition Scan, Questionnaire Administration, Tarlatamab
Procedure · Other · Drug
Lead sponsor
Asrar Alahmadi
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 2, 2026, 1:28 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

NCT04234568
View directory record Official record
Conditions
Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor
Interventions
Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Triapine
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 2, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials

NCT01546155
View directory record Official record
Conditions
Healthy Controls
Interventions
PET imaging
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 2, 2026, 1:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Self Focus in Bipolar Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study

NCT02253225
View directory record Official record
Conditions
Bipolar Disorder, Major Depression, Rumination
Interventions
Functional Magnetic Resonance Imaging (fMRI)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 2, 2026, 1:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

NCT02913131
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pyruvate (13C), MRI
Drug · Device
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 2, 2026, 1:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neural Mechanisms of Cost and Benefit Integration During Decision-Making, Aim 2: Acute & Lifetime Stress

NCT04060966
View directory record Official record
Conditions
Healthy
Interventions
Cold-Pressor Task (CPT), Control CPT, fMRI
Behavioral · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 64 Years
Enrollment
397 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 2, 2026, 1:28 AM EDT
Recruiting Phase 2 Interventional

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

NCT06031688
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab, Tepotinib
Procedure · Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Minutes and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
266
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 222 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 2, 2026, 1:28 AM EDT
Terminated Not applicable Interventional Results available

PET/MR for Rectal Cancer Treatment Monitoring and Surveillance

NCT04150705
View directory record Official record
Conditions
Rectal Cancer, Cancer of the Rectum
Interventions
FDG PET/MRI
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 2, 2026, 1:28 AM EDT
Completed Phase 1 Interventional

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

NCT01303705
View directory record Official record
Conditions
Metastatic Prostate Cancer, Cancer of the Prostate, Prostate Cancer
Interventions
Anti-OX40, Radiation, Cyclophosphamide
Drug · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 2, 2026, 1:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

NCT02730546
View directory record Official record
Conditions
Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7, Stage IIB Gastric Cancer AJCC v7, Stage IIIA Gastric Cancer AJCC v7, Stage IIIB Gastric Cancer AJCC v7
Interventions
Carboplatin, Computed Tomography, Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Oxaliplatin, Paclitaxel, Pembrolizumab, Positron Emission Tomography, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Procedure · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 2, 2026, 1:28 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural Mechanisms of Light Driven Analgesia

NCT07245303
View directory record Official record
Conditions
Musculoskeletal Pain, Fibromyalgia, Healthy Controls Group - Age and Sex-matched
Interventions
S-cone modulating visual stimulus, Equal Energy White Visual Stimulus, Green light visual stimulus (S-OFF), Evoked Pressure Pain Stimulus
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 2, 2026, 1:28 AM EDT
Not yet recruiting Not applicable Interventional

Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy

NCT07075705
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biopsy of Prostate, Magnetic Resonance Imaging, Micro-ultrasound Imaging
Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 2, 2026, 1:28 AM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

NCT06580054
View directory record Official record
Conditions
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Computed Tomography, Digital Photography, Magnetic Resonance Imaging, Pembrolizumab
Procedure · Other · Biological
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 2, 2026, 1:28 AM EDT